Antifibrotic Treatment in Idiopathic Pulmonary Fibrosis (IPF) and Progressive Pulmonary Fibrosis (PPF): Real-World outcomes from a Single-Center study
Polat Yuluğ, Demet | Televi, Beyza | Unal, Fatma Sevval | Sucu, Damla Hazal | Balci, Yuksel | Nayci, Sibel | Ozge, Cengiz | Ozgur, Eylem Sercan
Abstract Introduction: Antifibrotic therapies are widely used in both idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). We aim to compare the demographic, clinical characteristics, and long-term outcomes of IPF and PPF patients on antifibrotic treatment at 6-month and 1-year follow-ups. Methods and Materials: This was a retrospective single-center cohort study. Between January 2021 and January 2025, patients who initiated antifibrotic therapy were retrospectively included. Pulmonary function tests were recorded before treatment, at baseline, and at 6-month and 1-year follow-up visits. Additionally, baseline 6-minute walk test results and radiological data were also documented. Results: A total of 117 cases were included in the study, consisting of 7...
Ventilator-associated pneumonia due to extensive drug-resistant Acinetobacter baumannii: risk factors, clinical features, and outcomes
Ozgur, Eylem Sercan | Horasan, Şahin Elif | Ersöz, Gülden | Nayci Atış, Sibel | Kaya, Ali
Acinetobacter baumannii is characterized by a rapid development of resistance to the commonly used antimicrobial agents. We investigated the risk factors, clinical features, and outcomes in ventilatorassociated pneumonia (VAP) caused by extensive drug-resistant Acinetobacter baumannii (XDRAB). Clinical parameters and overall in-hospital mortality rates were compared between the VAP with and without XDRAB infection groups. This study showed that VAP caused by XDRAB was not associated with in-hospital mortality. However, it was related to high Simplified Acute Physiology Score II scores and increasing durations of hospital stays.